Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Universitaetsmedizin Goettingen

Verified siteinfo

Germany Robert-Koch-Strasse 40, Weende, 37075 Goettingen, Germany

  • 137 trials recruiting
  • Endocrine ophthalmopathy · Non-small cell lung cancer · Dermatitis atopic
  • Adults and children

About Specializations

Universitaetsmedizin Goettingen in Goettingen, Germany specialises in clinical trials of conditions such as Endocrine ophthalmopathy, Non-small cell lung cancer, Dermatitis atopic, Diffuse large B-cell lymphoma, and other specialisations. This site conducts important research.

Main research areas of the site

Psychiatry and Psychology

The clinical research at Universitaetsmedizin Goettingen is centered on psychiatry and psychology, with a strong focus on mental disorders and conditions linked to cognitive decline. The studies here are exploring ways to better understand and manage newly diagnosed early-to-mild dementia due to Alzheimer's disease, while also examining whether new approaches may support earlier recognition of the disease.

  • Research on Alzheimer's disease in its early stages
  • Clinical interest in mild cognitive impairment and early dementia
  • Testing potential tools that may improve diagnosis and treatment response

Overall, the site is contributing to research that aims to improve both the detection and management of early dementia, with investigators evaluating whether new therapies may help support brain health and disease control.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Robert-Koch-Strasse 40, Weende37075 GoettingenGermany
Open in maps ↗
Recruiting now
137 trials
Conditions studied
227
Partner status
Verified site

More sites in GoettingenGermany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

318 clinical trials

Cardiac failure

Recruiting

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Obesity+1

Recruiting

A Phase III Study of Lenbelintide in Adults with Obesity or Overweight and Weight‑Related Comorbidity Without Type 2 Diabetes

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD6234
  • Sponsor:AstraZeneca AB

Type 2 diabetes mellitus+2

Recruiting

Effect of lenbelintide (AZD6234) on body weight in adults with type 2 diabetes and obesity or overweight

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD6234
  • Sponsor:AstraZeneca AB

Chronic kidney disease

Recruiting

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Craniocerebral injury

Recruiting

Phase 2a Study of Safety, Tolerability and Efficacy of Intranasal Cenegermin in Adults with Moderate to Severe Subacute Traumatic Brain Injury

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cenegermin
  • Sponsor:Dompe' Farmaceutici S.p.A.

Cold urticaria

Recruiting

A study to evaluate the effectiveness of barzolvolimab in participants with cold urticaria and symptomatic dermographism

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Epinephrine
  • Sponsor:Celldex Therapeutics Inc.

Crohn's disease

Recruiting

A study to evaluate the effectiveness and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Crohn's disease

Recruiting

A study to evaluate the efficacy and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Colitis ulcerative

Recruiting

A study of duvakitug for patients with moderately to severely active ulcerative colitis to see if it works and is safe as maintenance therapy

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Colitis ulcerative

Recruiting

A study testing duvakitug for patients with moderately to severely active ulcerative colitis

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Palmoplantar pustulosis

Recruiting

A Study Testing How Well Bimekizumab Works and How Safe It Is for Adults with Palmoplantar Pustulosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bimekizumab
  • Sponsor:UCB Biopharma

Vitiligo+2

Recruiting

Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.